News Angelini rapped for criticism of EMA approval Angelini has been rapped under the UK pharma industry's code of practice for criticising licensing decisions made by the EMA and other breaches.
News Drug-resistant epilepsy drug Ontozry backed by NICE NHS patients in England and Wales with drug-resistant epilepsy are in line for access to another treatment option, after NICE recommended routine use of Angelini group company Arvelle Pharm
Oncology Closing the global evidence gap in oncology, with Flatiron H... Kate Estep discusses Flatiron’s AI-powered oncology intelligence platform, Telescope, and how AI tools are changing research decisions.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.